Core Viewpoint - The FDA has granted Fast Track Designation (FTD) to Irpagratinib (ABSK-011), a selective FGFR4 inhibitor developed by the company, for the treatment of advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have previously received immune checkpoint inhibitors (ICI) and multi-target kinase inhibitors (mTKI) [1][4]. Group 1: FDA Fast Track Designation - The Fast Track Designation aims to expedite the development and review process of innovative therapies for serious diseases with unmet clinical needs, allowing for earlier and more frequent communication with the FDA [3]. - The designation will accelerate global clinical development and registration processes for Irpagratinib, potentially shortening the time to market [3]. Group 2: Clinical Data and Efficacy - In a Phase I clinical study presented at the 2024 ESMO annual meeting, Irpagratinib demonstrated an objective response rate (ORR) of 46.7% and a median progression-free survival (mPFS) of 5.5 months in HCC patients with FGF19 overexpression who had progressed after ICI and mTKI treatments [4]. - The safety and tolerability profile of Irpagratinib was reported to be favorable [4]. Group 3: Combination Therapy Exploration - The company is also exploring combination therapy with Irpagratinib and Roche's PD-L1 inhibitor Atezolizumab, which has shown an ORR exceeding 50% and mPFS over 7 months in both treatment-naive and previously treated FGF19 overexpressing HCC patients, with no new safety signals observed [4]. - The results suggest a potential synergistic mechanism between FGFR4 inhibitors and ICIs, aligning with accumulating preclinical and translational research evidence [4]. Group 4: Precision Oncology Shift - Irpagratinib represents a significant shift towards precision oncology in the treatment of liver cancer, moving away from relatively non-selective systemic therapies [5]. - The development path of Irpagratinib aligns closely with the global trend towards molecularly driven precision therapies, aiming to establish a new treatment paradigm for patients with FGF19 overexpression [5].

Core Viewpoint - The FDA has granted Fast Track Designation (FTD) to Irpagratinib (ABSK-011), a selective FGFR4 inhibitor developed by the company, for the treatment of advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have previously received immune checkpoint inhibitors (ICI) and multi-targeted kinase inhibitors (mTKI) [1][3][4]. Group 1: FDA Fast Track Designation - The Fast Track Designation aims to expedite the development and review process of innovative therapies for serious diseases with unmet clinical needs, allowing for earlier and more frequent communication with the FDA [3]. - The designation will accelerate global clinical development and registration processes for Irpagratinib, potentially shortening the time to market [3][4]. Group 2: Clinical Data and Efficacy - In a Phase I clinical study presented at the 2024 ESMO annual meeting, Irpagratinib demonstrated an objective response rate (ORR) of 46.7% and a median progression-free survival (mPFS) of 5.5 months in HCC patients with FGF19 overexpression who had progressed after ICI and mTKI treatments [4]. - The safety and tolerability profile of Irpagratinib was reported to be favorable, showing significant advantages over previous treatment data for HCC patients [4]. Group 3: Combination Therapy Exploration - The company is also exploring combination therapy with Irpagratinib and Roche's PD-L1 inhibitor Atezolizumab, which has shown an ORR exceeding 50% and mPFS over 7 months in both treatment-naive and previously treated HCC patients with FGF19 overexpression [4]. - No new safety signals were observed in the combination therapy, suggesting a potential synergistic mechanism between FGFR4 inhibitors and ICIs [4]. Group 4: Precision Oncology Shift - Irpagratinib represents a significant shift towards precision oncology in the treatment of liver cancer, aligning with global trends in molecularly driven precision therapies [5]. - The development of Irpagratinib aims to establish a new treatment paradigm for patients with FGF19 overexpression, promoting a more targeted approach in HCC treatment [5].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Abbisko Cayman Limited 和譽開曼有限責任公司 （於開曼群島註冊成立的有限公司） （股份代號：2256） 自願性公告 FGFR4抑制劑依帕戈替尼獲FDA快速通道資格，用於 治療HCC患者 和譽開曼有限責任公司（「本公司」，連同其附屬公司統稱「本集團」）謹在此隨附 新聞稿，以告知本公司股東及潛在投資者，本公司之附屬公司上海和譽生物醫 藥科技有限公司（「和譽醫藥」）宣佈，美國食品藥品監督管理局（「FDA」）已授 予和譽醫藥自主研發的高選擇性小分子FGFR4抑制劑依帕戈替尼(Irpagratinib/ ABSK-011)快速通道資格認定（「FTD」），用於治療既往接受過免疫檢查點抑制劑 （「ICIs」）和多靶點激酶抑制劑（「mTKIs」）治療，且存在FGF19過表達的肝細胞癌 （「HCC」）患者。 此為本公司刊發的自願性公告。本集團無法保證依帕戈替尼最終將成功獲批上 市。本公司股東及潛在投 ...

Core Insights - The article discusses the approval of the high-selectivity small molecule inhibitor, Pimitinib, by the National Medical Products Administration (NMPA) in China for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) in adult patients [2] - Pimitinib is notable for being developed through a global synchronized clinical trial approach, marking a significant achievement for domestic pharmaceutical companies in China [2] Group 1: Product Development and Approval - Pimitinib is the first innovative drug in China to conduct multi-center Phase III clinical trials simultaneously in the US, Europe, and China, using the same data for the New Drug Application (NDA) [2] - The development of Pimitinib took 9 years and 7 months, significantly shorter than the global average of 15 years for innovative drugs [2] - The drug addresses a clear unmet clinical need for patients with TGCT, a rare disease with an incidence rate of approximately 44 per million in China [2] Group 2: Commercialization and Financial Aspects - The company signed a licensing agreement with Merck in December 2023, granting Merck commercialization rights for Pimitinib in mainland China, Hong Kong, Macau, and Taiwan, along with exclusive global commercialization rights [3] - The company received an upfront payment of $155 million and is set to receive over $400 million in milestone payments and ongoing sales royalties, providing substantial funding for future research and development [3] - Pimitinib has also received breakthrough therapy designation from the FDA and priority medicine designation from the EMA, with application processes in both regions progressing smoothly [3] Group 3: Future Development Pipeline - The company has established a research pipeline with over 20 projects, including a core liver cancer inhibitor, Ipagotene, which has entered critical registration clinical stages [3] - The company is also expanding its focus into areas such as autoimmune diseases, cardiovascular conditions, and diabetes [3]

Core Viewpoint - The report from CICC indicates that HeYu-B's CSF-1R inhibitor, Pimitinib (Beijiemai), has been approved for marketing in China for the treatment of inoperable giant cell tumors of the tendon sheath, marking the company's first self-developed innovative drug approval [1] Group 1: Approval Details - Pimitinib's approval speed exceeded expectations, taking just over six months from the acceptance of its application in June 2025 to approval [1] - The approval is based on the results of the global Phase III MANEUVER clinical trial, which showed a 25-week overall response rate (ORR) of 54% compared to 3.2% for the placebo, with significant improvements in joint mobility and pain indicators [1] Group 2: Future Outlook - The report suggests monitoring the progress of Pimitinib's U.S. market entry, the registration clinical progress of Ipagofitinib in the second-line setting, and the first-line clinical plans [1] - Potential data readout opportunities for ABSK061 and ABSK043, as well as the development progress of early molecules including ABSK131 and ABSK141, are also highlighted [1] - The firm maintains an "outperform" rating for the stock with a target price of HKD 20 [1]

Group 1 - The core viewpoint of the report is that the company maintains its net profit forecasts for 2025 and 2026 at 48 million and 320 million respectively, with a target price of 20 HKD, indicating a potential upside of 48.8% from the current stock price [1] - The company recently announced the approval of its first self-developed innovative drug, Pimiatinib, for the treatment of unresectable tenosynovial giant cell tumors (TGCT) in China [2] - The approval of Pimiatinib was faster than expected, taking just over six months from the acceptance of its application, based on strong clinical evidence from the global Phase III MANEUVER study, which showed an overall response rate (ORR) of 54% compared to 3.2% for placebo [3] Group 2 - The company has made progress in its pipeline, with the completion of the first patient dosing in a Phase II trial of FGFR2/3 inhibitor ABSK061 for achondroplasia [4] - Additionally, results from a Phase II trial of oral PD-L1 inhibitor ABSK043 combined with Furmetinib for non-small cell lung cancer (NSCLC) were presented at the ESMO Asia 2025 conference, showing a disease control rate (DCR) of 71% without observed dose-limiting toxicities [4]

Group 1 - The core viewpoint of the report is that the company maintains its net profit forecasts for 2025 and 2026 at 48 million and 320 million yuan respectively, with a target price of 20 HKD, indicating a potential upside of 48.8% from the current stock price [1] - The company recently announced the approval of its self-developed innovative drug, Pimiatinib, in China for the treatment of unresectable tenosynovial giant cell tumors (TGCT), marking its first approved product [2] - The approval of Pimiatinib was faster than expected, taking just over six months since the application was accepted, based on strong clinical evidence from the global Phase III MANEUVER study, which showed an overall response rate (ORR) of 54% compared to 3.2% for placebo [3] Group 2 - The company has reported progress in its pipeline, including the completion of the first patient dosing in a Phase II trial for FGFR2/3 inhibitor ABSK061 for achondroplasia [4] - Additionally, results from a Phase II trial of oral PD-L1 inhibitor ABSK043 combined with Furmetinib for non-small cell lung cancer (NSCLC) were presented at the ESMO Asia 2025 conference, showing a disease control rate (DCR) of 71% without observed dose-limiting toxicities [4]

Core Viewpoint - The Hong Kong stock market has experienced a significant rise in innovative pharmaceuticals, with the Hang Seng Healthcare Index increasing by 102.76% from the beginning of the year to its peak in September, followed by a decline of 19.06% by December 22. Despite this, the company He Yu has seen a remarkable stock price increase of 370.95% this year, driven by the approval of its core product, Pimicotinib, in China [1][2][5]. Group 1: Product Approval and Market Impact - He Yu announced the approval of its drug Beijiemai (Pimicotinib) by the NMPA, marking it as the first systemic treatment for tenosynovial giant cell tumor (TGCT) in China [2][5]. - The approval process for Beijiemai was expedited, receiving priority review in May and being approved within six months after its NDA application was accepted [6][7]. - The drug has shown strong and durable tumor relief efficacy in clinical trials, providing significant evidence for its long-term safety and effectiveness [6][7]. Group 2: Financial and Market Potential - Pimicotinib is expected to generate substantial revenue, with estimates suggesting it could reach peak sales of approximately $1.5 billion globally [8][9]. - The company has secured a lucrative partnership with Merck, which includes an upfront payment of $70 million and potential total transaction value of up to $606 million, reflecting strong confidence in the drug's market potential [7][9]. - The approval of Pimicotinib is anticipated to enhance the company's cash flow, supporting further innovation and development of its oncology pipeline [9][10]. Group 3: Innovation Pipeline and Valuation - He Yu has established a robust pipeline of 22 differentiated innovative drugs, focusing on precision oncology and immunotherapy, with several candidates showing potential for being first-in-class or best-in-class [9][10]. - The company has been actively repurchasing shares, with a total of 39 buybacks this year, indicating a commitment to returning value to shareholders [10]. - Compared to other biopharma companies, He Yu's price-to-sales (P/S) ratio of 13.38 suggests significant upside potential in valuation, especially with the successful commercialization of Pimicotinib [10].

Core Viewpoint - The Hong Kong stock market has experienced a significant rise in innovative pharmaceuticals, with the Hang Seng Healthcare Index increasing by 102.76% from the beginning of the year to its peak in September, followed by a decline of 19.06% by December 22. Despite this, the company He Yu has seen a remarkable stock price increase of 370.95% this year, driven by the approval of its core product, Pimicotinib, in China, marking a critical milestone for the company [1][4]. Group 1: Product Approval and Market Impact - He Yu's Pimicotinib, a first-in-class drug for treating tenosynovial giant cell tumors (TGCT), has received approval from the National Medical Products Administration (NMPA) in China, representing a significant step towards global commercialization [4][5]. - The approval process for Pimicotinib was expedited, with the drug being accepted for priority review in May and receiving approval just over six months later, highlighting the efficiency of He Yu's research and development system [5][6]. - The MANEUVER study presented at the European Society for Medical Oncology (ESMO) demonstrated Pimicotinib's strong and durable tumor relief efficacy, providing critical evidence for its long-term safety and effectiveness [6][7]. Group 2: Financial and Strategic Developments - He Yu has entered a lucrative partnership with Merck, which includes a high upfront payment and potential milestone payments, indicating strong confidence in Pimicotinib's market potential, with total deal value potentially reaching $606 million [6][8]. - The market for TGCT treatment is currently dominated by Pexidartinib, which has significant safety concerns, positioning Pimicotinib as a safer and more effective alternative, with expectations of substantial revenue growth [7][8]. - He Yu's innovative pipeline includes multiple promising candidates, with ongoing developments in various drug candidates that could further enhance the company's market position and revenue streams [8][9]. Group 3: Valuation and Investor Returns - He Yu has been actively repurchasing shares, with a total of 39 buybacks this year, reflecting a commitment to returning value to shareholders while maintaining a low price-to-sales (PS) ratio of 13.38, suggesting significant upside potential compared to peers [9]. - The successful commercialization of Pimicotinib is expected to generate stable revenue and cash flow, supporting further innovation and development within the company [8][9]. - The company is well-positioned to transition into a leading global biopharmaceutical player, leveraging its innovative capabilities and expanding its market presence [9].

Core Insights - The company, He Yu Pharmaceutical, is advancing in "source innovation" through strong new drug development, global clinical capabilities, and international collaborations [1][2] - The company has a robust pipeline with 22 drugs in development, over 10 of which are in clinical stages, highlighted during the R&D Day event on October 30 [1][2] R&D Strategy - He Yu emphasizes a dual-driven strategy of "depth + breadth" to enhance its pipeline, focusing on developing differentiated innovative therapies for unmet clinical needs [2][7] - The company has maintained a compound annual growth rate of 54% in R&D investment since its inception, ensuring a strong pipeline of over 10 clinical-stage oncology products [7] Key Products - The core product, Pimicotinib, is the first Chinese-developed CSF-1R inhibitor entering global Phase III clinical trials, with breakthrough therapy designation from multiple regulatory agencies [4][6] - Pimicotinib has shown significant potential in treating TGCT and other indications, with a projected global peak sales exceeding $2 billion [4][5] Clinical Data - Recent data presented at the ESMO Congress 2025 demonstrated Pimicotinib's strong and durable tumor response in TGCT patients, confirming its potential as a best-in-class treatment [5] - The drug is currently under priority review in China and is expected to submit an NDA in the U.S. by the end of the year, with potential approvals in 2026 [6] Pipeline Development - The company is also exploring FGFR and KRAS targets, with the FGFR4 inhibitor, Absk-011, showing promising clinical results in advanced HCC patients [8][9] - Absk-011 has received breakthrough therapy designation and is positioned to become a leading targeted therapy for liver cancer [8][9] Market Potential - Approximately 30% of global HCC patients have FGF19 overexpression, indicating a significant market opportunity for Absk-011 upon approval [9] - The company is advancing multiple promising candidates, including oral small molecule PD-L1 inhibitors and other innovative therapies, enhancing its commercial prospects [9][10] Financial Outlook - He Yu holds over 2 billion yuan in cash and is recognized for enhancing investor returns through stock buybacks while being in the early stages of commercialization [10] - Recent analyst reports have issued "buy" ratings for the company, with target prices indicating substantial upside potential [10]